What is the difference between Chonluten and PE-22-28?

Chonluten: A short synthetic peptide bioregulator (Glu-Asp-Gly) from the Khavinson family, marketed for bronchial/lung epithelium support. Evidence is largely Russian-language and preclinical.... PE-22-28: PE-22-28 is a 7-amino-acid synthetic analog of spadin, a peptide fragment (residues 22-28) of the 44-aa propeptide (PE) released during post-translational maturation of sortilin (the neurotensin recep...

Chonluten vs PE-22-28

Q: Can you stack Chonluten and PE-22-28?

Chonluten (immune) and PE-22-28 (cognitive) are in different categories and are sometimes researched together in combined protocols. Consult a licensed provider before combining any compounds.

Head-to-head comparison of Chonluten and PE-22-28 — mechanism, side effects, legal status, and pricing.

Chonluten

A short synthetic peptide bioregulator (Glu-Asp-Gly) from the Khavinson family, marketed for bronchial/lung epithelium support. Evidence is largely Russian-language and preclinical.

Profile Prices Testing

PE-22-28

PE-22-28 is a 7-amino-acid synthetic analog of spadin, a peptide fragment (residues 22-28) of the 44-aa propeptide (PE) released during post-translational maturation of sortilin (the neurotensin receptor-3). It is studied in preclinical models as a fast-acting antidepressant that works by selectively blocking the TREK-1 two-pore potassium channel. There is no established use for hair growth — that is a separate compound and the two should not be confused.

Profile Prices Testing

Chonluten

PE-22-28

Category

Immune

Cognitive

Legal Status

Research Only

Mechanism

Proposed tissue-specific peptide-bioregulator activity in respiratory epithelium; not established by independent research.

PE-22-28 is a highly selective antagonist of the TREK-1 (KCNK2) two-pore-domain potassium channel, with reported in vitro IC50 near 0.12 nM — roughly 300–500× more potent than the parent spadin peptide (IC50 ~40–60 nM). TREK-1 is enriched in serotonergic neurons of the dorsal raphe nucleus; blocking it depolarizes these neurons and enhances 5-HT transmission to limbic targets. In rodents, TREK-1 blockade also increases hippocampal neurogenesis and synaptic markers (PSD-95, BDNF), which is hypothesized to underlie its rapid-onset antidepressant signature.

Half-life

—

Short in rodents; modified G/A-PE 22-28 analog extended to ~21–23 hours

Side Effects

Not well characterized

Unknown in humans — no clinical safety data
Rodent studies did not report overt toxicity at effective doses
Theoretical: potassium channel modulation could affect cardiac repolarization at higher exposures

Where Researchers Are Buying

Live · updated daily

COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower

Chonluten

Best $/mg

$3.50/mg

BioLongevity LabsC

1 trusted vendor listing

Compare all 1 vendor

PE-22-28

Best $/mg

$4.90/mg

Ion PeptideA

3 trusted vendors listing

Compare all 3 vendors

Lab Verification

COA corpus from Disclosed Labs — independently tested batches only.

Chonluten

COAs

99.6%

Avg purity

Labs

Full testing data

PE-22-28

COAs

99.6%

Avg purity

Labs

Full testing data

Chonluten Research Summary

Primarily Russian institutional studies; no large independent controlled human trials.

PE-22-28 Research Summary

Mazella, Borsotto and colleagues at Nice, France identified spadin (Mazella et al., PLoS Biology 2010, PMID 20405001) and subsequently developed shortened PE 22-28 analogs with ~300× improved TREK-1 affinity and longer in vivo half-life (Djillani et al., Front Pharmacol 2017, PMID 28955242). In mouse antidepressant assays (forced swim, tail suspension, novelty-suppressed feeding), acute or 4-day IP dosing at ~3–4 μg/kg produced effects comparable to chronic SSRI treatment; oral gavage at 1 mg/kg was also active. The G/A-PE 22-28 modification extended duration of action to ~21–23 hours. Chronic dosing did not produce cardiac or seizure signals in rodents. No human clinical trials have been conducted. A detailed review of TREK-1 blockers for depression is available in Djillani et al., Pharmacol Ther 2019 (PMID 30291907).

Key references

Can you stack Chonluten and PE-22-28?

Chonluten (Immune) and PE-22-28 (Cognitive) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.

Other comparisons

PE-22-28 vs Selank Chonluten vs Selank PE-22-28 vs Semax Chonluten vs Semax Dihexa vs PE-22-28 Chonluten vs Dihexa NAD+ vs PE-22-28 Cerebrolysin vs PE-22-28

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.